TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06491446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-2280
Description: Different strength of ABI 2280 will be administered in different cohorts.~Other: Placebo Matching placebo will be administered.
Study: NCT04327700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBionic
Description: Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three courses of 60-minute treatments per day, administered in the morning, at noon and in the evening at the patient's home, with the exception of the first 60-minute treatment, which will be delivered at the research site. Each 4 week treatment period will be considered a cycle of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Patients will receive 160 mg regorafenib (four 40 mg tablets) orally once daily for the first 3 weeks of each 4-week cycle per approved prescribing information.
Study: NCT06066788

Intervention type: OTHER
Group type: OTHER
Intervention: CHAMPS
Description: Cognitive Orientation to daily Occupational Performance is a performance-based treatment approach for children and adults who experience difficulties performing the skills they want to, need to or are expected to perform. Cognitive Orientation to daily Occupational Performance is a specifically tailored, active client-centered approach that engages the individual at the meta-cognitive level to solve performance problems. Focused on enabling success, the Cognitive Orientation to daily Occupational Performance Approach employs collaborative goal setting, dynamic performance analysis, cognitive strategy use, guided discovery, and enabling principles. These elements, all considered essential to the Cognitive Orientation to daily Occupational Performance Approach, are situated within a structured intervention format, and with parent/significant other involvement as appropriate.
Study: NCT05391503

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy
Description: Morning bright light for 60 minutes after awakening

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light therapy
Description: Placebo morning bright light for 60 minutes after awakening
Study: NCT04820075

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: improvement of preoperative shower
Description: Process about preoperative shower
Study: NCT06269133

Intervention type: DRUG
Intervention: REGN2810
Description: No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.

Intervention type: OTHER
Intervention: Platinum-doublet chemotherapy
Description: No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
Study: NCT05380427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
Study: NCT06397677

Intervention type: GENETIC
Intervention: Research Testing Performed (Laboratory)
Description: Blood collection (DNA, RNA)
Study: NCT05380427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-40101
Description: CU-40101，0.0025% CU-40101，0.005% CU-40101，0.01% CU-40101，0.02%
Study: NCT06650709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg orally twice daily on a continuous dosing schedule for a maximum of 3 x 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg intravenously on Day 1 and 15 of the 28 day cycle for a maximum of 3 cycles (Cycle 3, Day 15 will be omitted).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg intravenously on Day 1 of the 28 day cycle for a maximum of 3 cycles.
Study: NCT06655376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81-100 mg, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin dose will be adjusted per patient for a goal INR 2-3. The individualized daily dose could range anywhere from 0.5-2 mg to 5-7 mg. Oral.
Study: NCT06603116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treatment of class two cavities
Description: restorations in class 2 cavities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment of class two cavities
Description: restorations in class 2 cavities
Study: NCT06604273

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fibroblast Activation Protein Inhibitor
Description: PET CT imaging using the fibroblast activation protein inhibitor tracer
Study: NCT06603974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: After receiving the corresponding neoadjuvant treatment for 2 cycles, surgery was performed within 3-6 weeks after drug withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benmelstobart
Description: 1200mg, diluted to 250ml with normal saline, infusion time 60 ± 10mins. The first day of each cycle, 3 weeks (21 days) as a treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur
Description: it needs to be administered according to the patient\&#39;s body surface area\&lt; 40mg / time at 1.25m2; \&gt; 50mg/ time for 1.25m2 and \&lt;1.5m2; \&gt; 60mg/ time at 1.5m2; Oral, twice a day, after morning and evening meals, for 14 consecutive days, rest for 7 days, as a treatment cycle; Repeat every 3 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130mg/m2, administered on the first day of each cycle, repeated every 3 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel
Description: 260mg/m2, intravenous infusion, 30 minutes per infusion, once every 3 weeks, administered on the first and eighth days of each cycle
Study: NCT06586996

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06595160

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06592417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN016 injection
Description: JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.
Study: NCT05762757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colposcopy educational material
Description: -Will consist of a handout featuring education and information regarding colposcopies.
Study: NCT06589921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Modified-Release Tablets
Description: take the tablet under fed condition, 1 tablet at a time, once a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone Tablets
Description: ake the tablet under fed condition, 1 tablet at a time, three times a day.
Study: NCT06592677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condensed internet-delivered prolonged exposure (CIPE)
Description: 'Condensed Internet-delivered Prolonged Exposure' (CIPE) is an intervention designed for victims with symptoms of post-traumatic stress disorder (PTSD) soon after a traumatic incident. CIPE is a therapist-supported intervention that consists of four modules delivered over the internet. Central CIPE-interventions include psychoeducation of normal post-traumatic reactions, in-vivo exposure, imaginary exposure, and a breathing exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual (TAU)
Description: There is currently considerable heterogeneity regarding the interventional principles applied in the Treatment-as-usual (TAU) condition across municipal crisis teams. The national guidelines (The Norwegian Directorate of Health, 2016), recommends several interventional principles such as psychological first aid (PFA), psychoeducation regarding crisis reactions/symptoms of acute stress, normalization of such reactions, activation of social support, and practical assistance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual (TAU)
Description: There is currently considerable heterogeneity regarding the interventional principles applied in the Treatment-as-usual (TAU) condition across municipal crisis teams. The national guidelines (The Norwegian Directorate of Health, 2016), recommends several interventional principles such as psychological first aid (PFA), psychoeducation regarding crisis reactions/symptoms of acute stress, normalization of such reactions, activation of social support, and practical assistance.
Study: NCT06599476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioProtect Balloon Implant™ System
Description: The BioProtect Balloon Implant System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer, and by creating this space, to reduce the radiation dose delivered to the anterior rectum. The balloon is inserted into the perirectal space and inflated to its pre-defined size. The Balloon is made of biodegradable materials that maintain the space for the entire course of prostate radiation treatment and are absorbed by the patient's body over time
Study: NCT06600620

Intervention type: DEVICE
Intervention: Monitoring patients heart rythms with a wireless patch device
Description: The investigators will collect data in patients at high risk of atrial fibrillation (AF) without a known history of AF to determine clinical predicators of AF. This data will be used to generate virtual digital twins to to predict clinical and subclinical episodes of AF

Intervention type: DEVICE
Intervention: Monitoring patients heart rythms with a wireless patch device
Description: The investigators will collect data in patients at high risk of atrial fibrillation (AF) without a known history of AF to determine clinical predicators of AF. This data will be used to generate virtual digital twins to to predict clinical and subclinical episodes of AF

Intervention type: DEVICE
Intervention: Monitoring patients heart rythms with a wireless patch device
Description: The investigators will collect data in patients at high risk of atrial fibrillation (AF) without a known history of AF to determine clinical predicators of AF. This data will be used to generate virtual digital twins to to predict clinical and subclinical episodes of AF
Study: NCT06397677

Intervention type: DIAGNOSTIC_TEST
Intervention: Information Collected as Standard of Care
Description: High Resolution CT Scan (Chest), Pulmonary Function Testing (PFT), 6-Minute Walk Test (6MWT)

Intervention type: OTHER
Intervention: Research Testing Performed
Description: Blood collection (non-genetic), Buccal Swab, Rheumatologic Assessment, Pulmonary Assessment, Questionnaires
Study: NCT06600620

Intervention type: DEVICE
Intervention: Monitoring patients heart rythms with a wireless patch device
Description: The investigators will collect data in patients at high risk of atrial fibrillation (AF) without a known history of AF to determine clinical predicators of AF. This data will be used to generate virtual digital twins to to predict clinical and subclinical episodes of AF
Study: NCT06307028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SISTA-P Intervention
Description: This intervention is a small group discussion designed specifically for Black women. The sessions cover topics including: self pride and self-care; HIV \& PrEP education; assertiveness skills training; coping skills; skills practice; and barriers and facilitators to HIV prevention and PrEP.
Study: NCT06217809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention curriculum addresses sexual activity, abstinence, and adulthood preparation topics.
Description: The intervention is gender-specific, youth-co-led, and targets minorities through a 16-unit curriculum totaling 20 hours. Each participant and their parent/guardian will also receive one individual session with a case planner. Parents will receive 3 hours of parental support group. EmpowHer contains lessons and activities focusing on topics relating to sexual health and teen pregnancy prevention, focusing on adulthood preparation subjects (APS), such as parent-child communication, adolescent development, healthy life skills, and healthy relationships.
Study: NCT06126081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LBBP+GDMT
Description: LBBP is a procedure that the pacing lead is placed at the left bundle branch to achieve electrical and mechanical synchronization by pacing the left bundle branch area with stable pacing parameters.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GDMT
Description: GDMT is defined as the drug strategy for treatment of heart failure according to the current guidelines.
Study: NCT06602999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Receive a booklet on nutrition and physical activity for cancer survivors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instacart Voucher
Description: Receive Instacart grocery delivery voucher

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive nutrition navigation phone calls
Study: NCT06068595

Intervention type: OTHER
Group type: OTHER
Intervention: musculoskeletal ultrasound
Description: After clinical examination and medical interrogation, The investigating physician gives her decisions in the e-CRF according to the 5 axes: diagnosis (I), therapy (II), patient referral (III), prescription of additional tests (IV) and follow-up (V). The investigator performs the targeted musculoskeletal ultrasound with his personal ultrasound machine, following his usual operating procedure and give/keep the final diagnostic.
Study: NCT05922293

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blow bottle
Description: When you blow through a tube into water in a bottle, the pressure in the airways increases. This opens up the passageways between bronchioles, allowing air to flow behind the mucus and push it into the larger airways. This way, it will be easy to remove the mucus by coughing or huffing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blow bottle
Description: When you blow through a tube into water in a bottle, the pressure in the airways increases. This opens up the passageways between bronchioles, allowing air to flow behind the mucus and push it into the larger airways. This way, it will be easy to remove the mucus by coughing or huffing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: percussion
Description: Percussion technique should be performed for about 30 seconds and simultaneously with no more than three or four lower thoracic expansion exercises.~* Do this for a total of 10 breaths,~* Perform two huffs, and~* Cough.~* Close their mouth around the tube and exhale slightly forcefully for 3 seconds to produce bubbles. Such exhalations were conducted in two sets of ten, with a five-minute pause in between. For each subject, a fresh, disposable tube and bottle were utilized
Study: NCT06253598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Adenovirus Type 5
Description: Recombinant Human Adenovirus Type 5( H101 )was administered intratumorally on day 1 and 5 of cycle 1 and cycle 2. If the sum of the maximum diameters of the lesions was less than or equal to 10 cm, the total dose was 1.0×10\^12 vp . If the sum of the maximum diameters of the lesions was more than 10 cm, the total dose was 1.5×10\^12 vp. Recombinant Human Adenovirus Type 5 was diluted to 30% of the total tumor volume with normal saline before administration. Under the guidance of ultrasound, percutaneous puncture was performed to the center of the tumor, and the solution was uniformly injected into the tumor. If there are multiple lesions, the distribution of each lesion should be proportional to the size of the tumor. No more than 5 lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib was administered orally once daily started on day 1 of cycle 1 of the study until disease progression or unacceptable toxicity occurred or meet the end point of the study. For patients weighing less than 60 kg, the recommended daily dose was 8 mg once daily. For patients weighing ≥60 kg, the recommended daily dose was 12 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg was administered intravenously every 3 week started on day 1 of cycle 3 until disease progression or unacceptable toxicity occurred or meet the end point of the study.
Study: NCT04672226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PDE MAX
Description: PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
Study: NCT06603909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group 1: Use AI to assist nutrition management
Description: group1：AI-assisted nutrition management. group 2：Traditional nutrition management（through the hospital dietitian）.group 3:control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group 2：Traditional nutrition management（through the hospital dietitian）
Description: group 2：Traditional nutrition management（through the hospital dietitian）
Study: NCT06604611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG Oral Tablet Once Daily
Description: The intervention in this study is colchicine, patients randomized to the experimental group will be given oral colchicine 5mg once a day in 12 weeks.
Study: NCT06597045

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT with 18-FDG
Description: Study specific tests will include 18F-FDG PET/CT (specialised CT scan), electrocardiography (ECG), clinic blood pressure assessment, blood tests, urine sample, echocardiography (heart ultrasound) and tests on the fingertips (EndoPAT).~Positron emission tomography with computerised tomography (PET-CT) is a scanning technique in routine clinical use. It is the gold standard method for assessing blood vessel inflammation. A small amount of radioactive sugar (18F-FDG \[18F- fluorodeoxyglucose\]) is administered intravenously 90 minutes prior to the PET-CT scan. The distribution of uptake of this tracer is seen on the subsequent PET-CT scan. The CT component of this scan allows the PET image to be precisely aligned with anatomical structures (especially large blood vessels).

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT with 18-FDG
Description: Study specific tests will include 18F-FDG PET/CT (specialised CT scan), electrocardiography (ECG), clinic blood pressure assessment, blood tests, urine sample, echocardiography (heart ultrasound) and tests on the fingertips (EndoPAT).~Positron emission tomography with computerised tomography (PET-CT) is a scanning technique in routine clinical use. It is the gold standard method for assessing blood vessel inflammation. A small amount of radioactive sugar (18F-FDG \[18F- fluorodeoxyglucose\]) is administered intravenously 90 minutes prior to the PET-CT scan. The distribution of uptake of this tracer is seen on the subsequent PET-CT scan. The CT component of this scan allows the PET image to be precisely aligned with anatomical structures (especially large blood vessels).

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT with 18-FDG
Description: Study specific tests will include 18F-FDG PET/CT (specialised CT scan), electrocardiography (ECG), clinic blood pressure assessment, blood tests, urine sample, echocardiography (heart ultrasound) and tests on the fingertips (EndoPAT).~Positron emission tomography with computerised tomography (PET-CT) is a scanning technique in routine clinical use. It is the gold standard method for assessing blood vessel inflammation. A small amount of radioactive sugar (18F-FDG \[18F- fluorodeoxyglucose\]) is administered intravenously 90 minutes prior to the PET-CT scan. The distribution of uptake of this tracer is seen on the subsequent PET-CT scan. The CT component of this scan allows the PET image to be precisely aligned with anatomical structures (especially large blood vessels).